Hoth Therapeutics Inc. (NASDAQ:HOTH) shares rose 9.8% in premarket trading on Wednesday after the clinical-stage biopharmaceutical company announced an expansion of its artificial intelligence initiative through a new NVIDIA AI Enterprise subscription license.
The company said it has secured annual NVIDIA AI Enterprise Essentials licenses to bolster its GPU-driven infrastructure, enabling advanced machine learning and neural network modeling for pharmaceutical research. The technology is expected to accelerate data-driven drug discovery, preclinical modeling, and predictive analytics across Hoth’s development programs.
According to Robb Knie, CEO of Hoth Therapeutics, “Our continued investment in NVIDIA’s AI platform reflects our long-term commitment to integrating next-generation technology across our R&D programs.” He added that the company is “harnessing NVIDIA’s enterprise-grade AI infrastructure to accelerate the development of therapies like HT-001, HT-KIT, and our oncology programs.”
The new NVIDIA AI Enterprise environment will enable Hoth’s scientific and data teams to deploy predictive pharmacology and toxicity models, integrate multi-omic and patient-derived data, simulate clinical trials, and leverage secure GPU-accelerated cloud infrastructure to support research scalability.
Hoth Therapeutics said this initiative represents a key step in its digital transformation strategy, aimed at optimizing research efficiency, reducing development costs, and improving patient outcomes. The company continues to focus on developing innovative treatments for dermatological and oncological diseases, integrating AI to drive precision and speed in its therapeutic pipeline.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.